Valaciclovir Mechanism of action

Valaciclovir (INN) or valacyclovir (USAN) is an antiviral biologic acclimated in the administration of canker canker and canker zoster (shingles). It is a prodrug, getting adapted in vivo to aciclovir. It is marketed by GlaxoSmithKline beneath the barter name Valtrex or Zelitrex.
Valaciclovir is phosphorylated by viral thymidine kinase to acyclovir triphosphate (the alive metabolite) which again inhibits canker viral DNA archetype by aggressive inhibition of viral DNA polymerase, and by assimilation into and abortion of the growing viral DNA chain. When acclimated as a substrate for viral DNA polymerase, acyclovir triphosphate competitively inhibits dATP arch to the accumulation of 'faulty' DNA. This is area acyclovir triphosphate is congenital into the DNA fiber replacing abounding of the adenosine bases. This after-effects in the blockage of DNA synthesis, as phosphodiester bridges can best to be built, destabilizing the strand.